CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 6 incoming connections
- ScaleMarket cap is $2.05B, above the global median of $1.15B
- FinancialsAltman Z-Score 9.89: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.05BUSDvs all stocks (USD)
Revenue (TTM)
412.82MUSDvs all stocks (USD)
Profit Margin
-1.98%vs Diagnostics & Research peers
Beta
2.43xvs all stocks
52-Week Change
211.60%vs all stocks
Market Capitalization
2.05BUSDvs all stocks (USD)
Enterprise Value
1.37BUSDvs all stocks (USD)
Forward P/E
35.57xvs Diagnostics & Research peers
Price to Sales (TTM)
5.05xvs Diagnostics & Research peers
Price to Book (MRQ)
6.60xvs Diagnostics & Research peers
Enterprise to Revenue
3.33xvs Diagnostics & Research peers
Gross Margin
71.43%vs Diagnostics & Research peers
Profit Margin
-1.98%vs Diagnostics & Research peers
Operating Margin
1.53%vs Diagnostics & Research peers
Return on Assets (TTM)
-1.80%vs Diagnostics & Research peers
Return on Equity (TTM)
-2.37%vs Diagnostics & Research peers
Revenue (TTM)
412.82MUSDvs all stocks (USD)
Revenue per Share (TTM)
7.90USDUpdated Jul 18, 2026Quarterly Revenue Growth
39.00%vs Diagnostics & Research peers
Gross Profit (TTM)
284.37MUSDvs all stocks (USD)
EBITDA (TTM)
1.05MUSDvs all stocks (USD)
Net Income (TTM)
-8.19MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
38.99%vs Diagnostics & Research peers
Operating Cash Flow (TTM)
72.95MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
70.14MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Diagnostics & Research peers
Revenue
379.81MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
123.24MUSDFY2025 · Dec 31, 2025Gross Profit
256.57MUSDFY2025 · Dec 31, 2025Operating Income
-25.07MUSDvs all stocks (USD)
Pre-tax Income
-21.08MUSDFY2025 · Dec 31, 2025Income Tax Expense
271.00KUSDFY2025 · Dec 31, 2025Net Income
-21.35MUSDFY2025 · Dec 31, 2025EBIT
-25.07MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
1.05MUSDFY2025 · Dec 31, 2025Research & Development
71.43MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
210.21MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
9.17MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-21.35MUSDFY2025 · Dec 31, 2025Operating Cash Flow
47.02MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
65.98MUSDFY2025 · Dec 31, 2025Income Tax Paid
284.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-21.35MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
20.42MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
17.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
34.86MUSDFY2025 · Dec 31, 2025Other Non-cash Items
703.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
22.52MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
808.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-10.96MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-675.00KUSDFY2025 · Dec 31, 2025Net Acquisitions
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-145.93MUSDFY2025 · Dec 31, 2025Sale of Investments
154.67MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
8.75MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-87.77MUSDFY2025 · Dec 31, 2025Other Financing Charges
-13.62MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-101.39MUSDFY2025 · Dec 31, 2025Shares Outstanding
51.27MSharesUpdated Jul 18, 2026Float Shares
49.25MSharesUpdated Jul 18, 2026Shares Short
8.34MSharesUpdated Jul 18, 2026Short Ratio
8.60daysvs all stocks
Short % of Shares Outstanding
16.44%vs all stocks
% Held by Insiders
3.42%vs all stocks
% Held by Institutions
101.72%vs all stocks
Total Cash (MRQ)
187.18MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
3.62USDUpdated Jul 18, 2026Total Debt (MRQ)
24.50MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0781xvs Diagnostics & Research peers
Current Ratio (MRQ)
3.40xvs Diagnostics & Research peers
Book Value per Share (MRQ)
6.12USDUpdated Jul 18, 2026Total Assets
413.23MUSDvs all stocks (USD)
Total Current Assets
257.13MUSDFY2025 · Dec 31, 2025Total Liabilities
110.13MUSDFY2025 · Dec 31, 2025Total Non-current Assets
156.10MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
20.28MUSDFY2025 · Dec 31, 2025Total Current Liabilities
89.85MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
65.43MUSDFY2025 · Dec 31, 2025Other Short-term Investments
111.78MUSDFY2025 · Dec 31, 2025Accounts Receivable
42.63MUSDFY2025 · Dec 31, 2025Inventory
26.70MUSDFY2025 · Dec 31, 2025Accounts Payable
9.99MUSDFY2025 · Dec 31, 2025Short-term Debt
6.51MUSDFY2025 · Dec 31, 2025Deferred Revenue
4.65MUSDFY2025 · Dec 31, 2025Long-term Debt
19.68MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
418.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
50.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-735.36MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
303.10MUSDvs all stocks (USD)
52-Week Low
11.26USDUpdated Jul 18, 202652-Week High
40.47USDUpdated Jul 18, 202652-Week Change
211.60%vs all stocks
Beta
2.43xvs all stocks
50-Day MA
24.18USDUpdated Jul 18, 2026200-Day MA
19.55USDUpdated Jul 18, 2026Avg 10-Day Volume
835.89KSharesUpdated Jul 18, 2026Avg 30-Day Volume
931.36KSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-0.1600USDUpdated Jul 18, 2026Other Income / Expense
-5.19MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.71Profit Margin: -0.02
Financial Health
Altman Z-Score 9.89: safe zoneNotable
Altman Z-Score: 9.89
Supply Chain
Midstream position: 6 outgoing, 6 incoming connectionsNotable
Outgoing: 6.00Incoming: 6.00
High connectivity hub: 12 industry connectionsNotable
Total Connections: 12.00
Scale
Market cap is $2.05B, above the global median of $1.15BNotable
Market cap (USD): 2,052,431,180Global Median: 1,146,734,693.424
Levered free cash flow is $70.14M, above the global median of $16.24MNotable
Levered free cash flow (USD): 70,143,376Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
OC Oerlikon Corporation AG
Tier 1ProductionThroughput-Bound ConversionRiskSenseMaking
Bellwether Electronic Corp.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Keli Sensing Technology Nanjing Inc.
Tier 1ProductionThroughput-Bound ConversionSenseMakingRule
Shanghai Aerospace Automobile Electromechanical Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Anhui Honglu Steel Construction Group Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Tecnoglass Inc.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Toyou Feiji Electronics Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowSenseMaking
Greatoo Intelligent Equipment Inc.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Tangshan Sanyou Chemical Industries Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Arabian Drilling Company
Tier 1ProductionThroughput-Bound ConversionRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Iovance Biotherapeutics, Inc.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity